USDL sells Texas centers
In a move that effectively ends U.S. Diagnostic’s activities in Texas, the imaging center chain divested its facilities in the state last month in two transactions valued at more than $23 million. USDL sought to divest the Texas centers because of
In a move that effectively ends U.S. Diagnostics activities in Texas, the imaging center chain divested its facilities in the state last month in two transactions valued at more than $23 million. USDL sought to divest the Texas centers because of their poor financial performance, according to Joseph Paul, president and CEO. Sale proceeds will reduce the companys debt and overhead expenses for 1999 and increase its working capital, Paul said.
The company sold six centers in Houston to Dr. Mohammad Athari for $11.7 million. Four remaining Houston centers and four San Antonio facilities were sold to United Radiology Associates for $11.7 million. United Radiology Associates is run by USDL chairman Dr. L.E. Richey, who resigned from the post as a result of the transaction. He will, however, will continue to serve as an advisor to the company.
Where Things Stand with the Radiologist Shortage
June 18th 2025A new report conveys the cumulative impact of ongoing challenges with radiologist residency positions, reimbursement, post-COVID-19 attrition rates and the aging of the population upon the persistent shortage of radiologists in the United States.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
